Blue Matter Blog

Success in Rare Diseases, Part II: Optimizing Clinical Trial Design for the Rare Disease Ecosystem
September 24, 2020

In Part 1 of our series we introduced the rare disease (RD) ecosystem, which is defined by a small patient population with often heartbreakingly high unmet need. Here, in Part 2 of our series, we will discuss in more detail the overarching design requirements and key considerations for RD clinical trials. The entrance of a …

Building a Better Team: Blue Matter Academy
September 22, 2020

A key part of building a People First Culture is making sure team members have the tools, training, and support they need to do their jobs.  But it doesn’t stop there.  At Blue Matter, People Development is essential to the success of our employees and our company.  We want to  help team members continually develop …

They’re In! – The Results of Our Latest Values Survey
September 1, 2020

In an earlier article, we introduced readers to our quarterly Values Survey.  Our “People First” culture is incredibly important to all of our team members, and we work hard to maintain and continuously improve it.  That means staying true to our core values, which are based on a deep-seated desire to foster a happy, productive …

Success in Rare Diseases, Part I: Understanding the Rare Disease Ecosystem
August 31, 2020

It’s a safe bet that anyone reading this article is familiar with the concept of an ecosystem. When we think of an ecosystem, we most often imagine how one exists in nature: a complex web of living organisms and non-living components (such as water, air, soil, rocks, and so on), all interacting with one another …

A Happy Team: Direct Result of a “People First” Culture
August 25, 2020

If you’ve been following along in this series of articles on Blue Matter’s People First culture, then you probably know by now that building a happy and motivated team is super important to us.  In fact, it’s in our core values.  After all, taking every reasonable step to ensure a happy team is the right …

Living Our “People First” Culture: The Blue Matter Values Survey
August 11, 2020

In a previous article, Emily Hua described our People First culture and why It’s so important to us.  Today, I want to add a little more to the story by telling you about our Values Survey. Lots of companies out there will talk about their values.  However, not many are willing to truly measure whether …

Our Foundation: A “People First” Culture
July 30, 2020

If you’ve followed our blog for any length of time, you’ve probably noticed that we like to create high-value content on some of the leading topics in the biopharma industry.  Today, I want to shift gears and write a bit about Blue Matter as a company and its culture. We’re growing rapidly, always engaging with …

Blue Matter “Breakfast Club” Meeting #5: Practical Implications of the COVID-19 Crisis for Biopharma
July 28, 2020

The Blue Matter Breakfast Club is an ongoing series of discussion forums (now virtual due to COVID-19), hosted by our team in Europe.  These forums are by invitation, bringing together leading executives from biopharma companies and other organizations to discuss critical business issues. The fifth Breakfast Club meeting took place on 8th July 2020.  The …

T Cell-Based Therapies in Oncology: Landscape Evolution After a Turbulent 1H2020
July 7, 2020

Six months ago, we published an in-depth review of the cell-based immunotherapy landscape, including forward-facing declarations of 2020 data releases, filings, etc. that would address key outstanding questions, namely: Six months later, despite the unprecedented and unanticipated impact of COVID-19 on corporate operations, clinical trial functions, and regulatory body decision-making, there have been multiple key …

And Now for Something Completely Different: Basketball in India
June 5, 2020

It may come as no surprise that most of the charitable work Blue Matter does is in some way related to healthcare. Our focus as a company is, after all, on the life sciences.  However, sometimes we like to put our consulting skills to use outside of the healthcare space, in areas that speak to …

Blue Matter Statement on Racial Equality
June 4, 2020

We are deeply outraged and shattered by the death of George Floyd, yet another death among too many horrific killings driven by racism and hatred.  We stand together with Black Americans and all those who are affected by systemic and learned racism. Our Blue Matter team—which is made up of talented people from more than …

Blue Matter “Breakfast Club” Meeting #4: A Conversation with Dr. Thomas Lönngren, Former Exec. Dir. of the EMA
May 20, 2020

The Blue Matter Breakfast Club is an ongoing series of two-hour breakfast forums, hosted by our team in Europe.  These forums are by invitation, bringing together thought leaders and executives from biopharma companies and other organizations to discuss critical business issues. The fourth Breakfast Club meeting was a virtual event on 13th May 2020.  The guest …

Continuing the Fight Against Lung Cancer with the GO2 Foundation for Lung Cancer
May 18, 2020

Last year, we wrote about our charitable work with a great non-profit organization, the Addario Lung Cancer Foundation (ALCF).  We’re proud to say that our work has continued with this organization.  However, things have changed over the past year, as the ALCF has merged with the Lung Cancer Alliance to form the GO2 Foundation for …

The Science Won’t Sell Itself
May 12, 2020

“Plans are worthless, but planning is everything.” That well-known quote comes from Dwight D. Eisenhower, 34th president of the United States and former Supreme Commander of the Allied Expeditionary Force in Europe.  It’s a pithy quote—though perhaps a little overstated—that highlights the critical importance of planning for any serious undertaking. For a biopharmaceutical company, the …

The Rarest of Them All: Why Neglected Rare Diseases Require a Very Different Mindset
April 1, 2020

Introduction In previous articles, we explored several important aspects of rare diseases (RDs).  First, we showed how different authorities define the term “rare disease” (or “orphan disease”).  We also established a spectrum of rarity, ranging from those diseases that are considered common—with well-established treatment paradigms—to those that are “hyper-orphan,” affecting perhaps a couple of people …

The COVID-19 Challenge: How Pharma Can Adapt and Succeed in the Face of an Uncertain Future
March 31, 2020

Current Scenario: Challenges, Opportunities, and Critical Success Factors The current situation regarding COVID-19 is alarming.  At the time of publication, infection and death rates are continuing to rise rapidly in the United States, Spain, Switzerland, and many other European countries. In other countries like China, Italy, and Germany the situation appears to be resolving, but …

How Rare Is Rare? Making Sense of Rare Disease Definitions, Nomenclature, and Patient Numbers
March 20, 2020

Many people working in and around the health care system and the biopharmaceutical industry use the terms “rare disease” and “orphan disease” on a fairly regular basis.  Obviously, they refer to any disease that’s uncommon, often with few treatment options (or no treatment options).  But what do these terms really mean? What’s the actual definition …

Location, Location, Location: Why You Need a Systematic Approach to Locating Your European HQ
March 17, 2020

Location, Location, Location:  Most regard that as the first rule of real estate.  Simply put, it refers to the fact that a home’s value can vary dramatically based solely on its location.  Nice neighborhood with good schools, low crime, and beautiful tree-lined streets? In a place like that, a home will command a much higher …

Cell-Based Therapies: Navigating Challenges Through 2020 and Beyond
March 10, 2020

In Part 1 of this series, we reviewed recent developments and upcoming milestones that are shaping the cell-based therapy landscape. Here in Part 2, we explore the various factors and challenges that will influence how each cell-based therapy—and the class as whole—will perform in the marketplace over the next few years. Some of these factors …

Europe’s Got Talent II: Deciding Who to Hire and When
March 3, 2020

When a non-EU-based biopharmaceutical company decides to establish a presence in Europe, there are seemingly countless items that need to be managed, ranging from the highly strategic to the mundane.  One of the most important items is building the European team.  In the previous article, we outlined five ways in which hiring and recruiting differ …